- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
Expects full year 2026 revenue to be in the range of $1.0 billion to $1.02 billion
Published on Feb. 26, 2026
Got story updates? Submit your updates here. ›
Caris Life Sciences, a leading, patient centric, next-generation AI TechBio company and precision medicine pioneer, today reported financial results for the quarter and full year ended December 31, 2025. The company expects full year 2026 revenue to be in the range of $1.0 billion to $1.02 billion, representing growth of approximately 23% to 26% compared to full year 2025.
Why it matters
Caris Life Sciences is a pioneer in precision medicine, using comprehensive molecular profiling, advanced AI and machine learning to develop innovative solutions for early detection, diagnosis, monitoring, therapy selection and drug development. The company's strong financial performance and growth outlook demonstrate the increasing demand and adoption of its platform in the rapidly evolving precision medicine industry.
The details
Caris Life Sciences reported total revenue of $292.9 million for the fourth quarter of 2025, an increase of 125% over the prior year period, driven by a 199% growth in molecular profiling services revenue. For the full year 2025, the company reported total revenue of $812.0 million, an increase of 97% over the prior year. Gross margin improved significantly to 75% in Q4 2025 and 66% for the full year. The company also reported positive Adjusted EBITDA and free cash flow for both the quarter and full year.
- Caris Life Sciences reported financial results for the quarter and full year ended December 31, 2025.
- The company expects full year 2026 revenue to be in the range of $1.0 billion to $1.02 billion.
The players
Caris Life Sciences
A leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare.
David Dean Halbert
Founder, Chairman and CEO of Caris Life Sciences.
What they’re saying
“Demand for our platform continued to accelerate in 2025, driving strong growth in volume and revenue and expanding adoption across our solutions. We are focused on building on this momentum, advancing our pipeline, and are particularly excited about the planned launch of our Caris Detect solution in the first half of 2026, which we believe represents a significant growth opportunity for Caris and an important step forward for precision medicine.”
— David Dean Halbert, Founder, Chairman and CEO
What’s next
The company plans to launch its Caris Detect solution, a new MCED assay, in the first half of 2026, which it believes represents a significant growth opportunity.
The takeaway
Caris Life Sciences' strong financial performance and growth outlook demonstrate the increasing demand and adoption of its precision medicine platform, as the company continues to advance its pipeline and introduce new innovative solutions to transform healthcare.
